Health Care Technology
Company Overview of Nanthealth, LLC
NANTHEALTH, LLC, a transformational healthcare information technology company, provides cloud-based intelligent clinical operating systems for physicians, patients, payers, and researchers. It offers eviti|Advisor, a clinical decision support for oncologists; eviti|Advisor enterprise edition that enables identification of practice-preferred regimens for use by various providers in the practice, as well as facilitates identification of available clinical trials at the practice sites; and eviti|Connect, a Web-based platform that reduces the administrative time and tasks associated with obtaining preauthorization. The company also provides connectivity solutions, including DeviceConX (iSirona),...
9920 Jefferson Boulevard
Culver City, CA 90232
Founded in 2007
Key Executives for Nanthealth, LLC
Founder, Chairman and Chief Executive Officer
Senior Vice President of Strategy
Senior Vice President of Product Development
Compensation as of Fiscal Year 2015.
Nanthealth, LLC Key Developments
Genomics England Appoints NantHealth to Deliver Clinical Genomic Interpretation and Reporting Capabilities to Support 100K Genomes Project
Jun 4 15
NantHealth announced that its appointment by Genomics England to deliver the clinical interpretation and reporting of sequenced genomes for the much anticipated and coveted 100K Genomes Project. NantHealth, will implement its sophisticated, fully automated NantOmics Analytics Platform software (NantContraster) to deliver clinical genomic interpretation and reporting capabilities to support Genomics England’s 100K Genomes Project. The software will be used to rapidly transport (NantTransporter) and analyse raw data from sequenced genomes of consented patients and transform it into meaningful, actionable information, which can be provided both as printable reports and in interactive form, via NantHealth’s fast, dynamic and the mobile enabled NantCancer Genome Browser. This clinical interpretation of sequenced data is powered by a sophisticated, web-based decision support tool that uses complex logic and well proven algorithms to optimise and enable clinical genomic research in real-time. The information can be displayed at increasingly in-depth views; from a whole genome level, which provides immediate confirmation of detected variants and individual genetic alterations that make each patient’s disease unique, to the single-base level, which allows for an in-depth view of each of the full three billion bases.
University Hospital Southampton NHS Foundation Trust (UHS) and Nanthealth Announces Strategic Partnership to Deliver Precision Medicine for Cancer Patients
Jun 4 15
University Hospital Southampton NHS Foundation Trust (UHS) and NantHealth announced a strategic partnership with the aim of delivering and transforming cancer services using the most advanced molecular genomic and proteomic diagnostics, treatment decision support and unique IT integration capabilities for better informed precision treatment selection and care coordination. Under the three-year programme, NantHealth will enable UHS to rapidly transport raw data from the sequencing machines to NantHealth's UK based supercomputing infrastructure through the NantTransporter, and access NantHealth's automated NantOmics Analytics Platform (NantContraster) for genomics sequencing interpretation and annotation. In addition, NantHealth will generate rapid and timely clinical reporting to support personalised treatment decision making for cancer patients, based on evidence-based outcomes among patients with a similar genetic signature. With this partnership UHS will integrate advanced genomic and proteomic capabilities into its existing laboratory and with their agreement engage cancer patients to provide genome samples for sequencing. The enormous volumes of data generated will be quickly processed via NantHealth's hyper secure UK data centre. It will then utilise comprehensive clinical data to identify potential clinical trial participants for recruitment into targeted trials. Using NantHealth's intelligent clinical operating system (cOS), the organizations will work to incorporate NantHealth's technology platforms to capture relevant cancer clinical and outcomes data from the Trust. This strategic collaboration will help identify future patients suitable for clinical trials at the earliest possible stage and will record outcomes delivered as a result of therapy decisions that are made, in this era of targeted therapy and immuno-oncology. By converging molecular science, computer science and real world big data infrastructure capabilities, the cOS platform will empower providers, patients and commissioners to coordinate the best possible care, monitor outcomes and control cost in real-time.
Toumaz Limited Agrees with NantHealth LLC to Terminate its North American Distribution Agreement for its SensiumVitals® Wireless Vital Signs Monitoring System
Mar 3 15
Toumaz Limited has agreed with NantHealth LLC to terminate its North American distribution agreement for its SensiumVitals® wireless vital signs monitoring system. This change, instigated by the Group, will allow Toumaz to address the key US market in a substantially more focused manner. The North American distribution rights for SensiumVitals® revert to Toumaz with immediate effect, in return for an undisclosed payment which will have a minimal impact on the Group's overall cash position. The region accounts for c.50% of the potential $1.5 billion global market for hospital-based wireless monitoring. The Group will position a small business development team in the US to support existing customers, follow through on leads generated by NantHealth LLC, introduce SensiumVitals® to the larger hospital groups and evaluate Toumaz's options for an accelerated deployment in the US. The Group will provide a further update on its strategy later this year. In Rest of World territories, interest in the system continues to build. SensiumVitals® has been deployed in hospitals in the UK, France, Italy, Germany, Portugal, and Australia - as well as the US. A growing number of these deployments are moving from initial evaluation to full-scale integration with hospital IT systems. Worldwide, the Group has a qualified pipeline of 200 hospitals.
Similar Private Companies By Industry
Recent Private Companies Transactions